Continuous R&D investment: Robust pharma R&D expenditure and patent number growth have sustained the underlying growth of China clinical trials in the past
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · page 10 of 58
Data refers to enterprises above designated annual revenue size (>20M RMB). Exchange rate 6.25 used.
Consulting deck · industry_trends · analyze_data · dense density
Slide locked Sign in to view
Slide schematic 5/5
chart 2/2 list 1/1 source-note 1/1 title 1/1
Components 5
bar-vertical bar-vertical bullet source-note action-title
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 1
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.